A phase I study of oral paclitaxel with a novel P-glycoprotein inhibitor, HM30181A, in patients with advanced solid cancer

Cancer Research and Treatment

Volumn 46, Issue 3, 2014, Pages 234-242

  Lee, Hyun Jung ^a,b   Heo, Dae Seog ^b,c   Cho, Joo Youn ^b   Han, Sae Won ^b,c   Chang, Hye Jung ^b,d   Yi, Hyeon Gyu ^b,e   Kim, Tae Eun ^b,f   Lee, Se Hoon ^b,c   Oh, Do Youn ^b,c   Im, Seock Ah ^b,c   Jang, In Jin ^b   Bang, Yung Jue ^b,c  

^a Dongguk University Ilsan Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Konyang University College of Medicine   (South Korea)

^e Inha University Hospital   (South Korea)

^f Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Administration; Clinical trial; Oral; P glycoprotein; Paclitaxel; Pharmacokinetics; Phase 1

Indexed keywords

GLYCOPROTEIN P INHIBITOR; HM 30181A; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; DIARRHEA; DISEASE DURATION; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FEVER; DRUG HYPERSENSITIVITY; DYSPEPSIA; FACE EDEMA; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEAN RESIDENCE TIME; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROPATHY; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRURITUS; RASH; SOLID TUMOR; STOMATITIS; THERAPY DELAY; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84905256881     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2014.46.3.234     Document Type: Article

References (24)

1. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995;332:1004-14.
2. Broker LE, Veltkamp SA, Heath EI, Kuenen BC, Gall H, Astier L, et al. A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183. Clin Cancer Res. 2007;13:3906-12.
3. Hong YS, Kim KP, Lim HS, Bae KS, Ryu MH, Lee JL, et al. A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: crossover comparisons with intravenous paclitaxel. Invest New Drugs. 2013;31:616-22.
4. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A. 1997;94:2031-5.
5. Malingre MM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, et al. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. Cancer Chemother Pharmacol. 2001;47:347-54.
6. Malingre MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM, et al. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer. 2001;84:42-7.
7. Kwak JO, Lee SH, Lee GS, Kim MS, Ahn YG, Lee JH, et al. Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel. Eur J Pharmacol. 2010;627:92-8.
8. Kim TE, Gu N, Yoon SH, Cho JY, Park KM, Shin SG, et al. Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers: single- and multiple-dose randomized, placebo-controlled studies. Clin Ther. 2012;34:482-94.
9. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) [Internet]. Bethesda: Cancer Therapy Evaluation Program; 2006 [cited 2013 Aug 6]. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_ applications/docs/ctcaev3.pdf.
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
11. Paek IB, Ji HY, Kim MS, Lee GS, Lee HS. Simultaneous determination of paclitaxel and a new P-glycoprotein inhibitor HM- 30181 in rat plasma by liquid chromatography with tandem mass spectrometry. J Sep Sci. 2006;29:628-34.
12. Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000;17:1278-83.
13. Kobayashi M, Oba K, Sakamoto J, Kondo K, Nagata N, Okabayashi T, et al. Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan. Gastric Cancer. 2007;10:52-7.
14. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther. 2006;112:457-73.
15. Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist. 2001;6 Suppl 3:30-5.
16. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008;26:1642-9.
17. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358:1663-71.
18. Baird RD, Tan DS, Kaye SB. Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat Rev Clin Oncol. 2010;7:575- 82.
19. Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010;7:455-65.
20. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 2002;62:6938-43.
21. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor- free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004;10:3708-16.
22. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002;8:1038-44.
23. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590-8.
24. Darby RA, Callaghan R, McMahon RM. P-glycoprotein inhibition: the past, the present and the future. Curr Drug Metab. 2011;12:722-31.